Cystine

Cystine

SCHEMBL5223299

NC(=O)O.NC(CSSCC(N)C(=O)O)C(=O)O

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 8/20 0.50
NOS1 P29475 6/20 0.50
NOS3 P29474 5/20 0.50
ARG1 P05089 1/20 0.47
ARG2 P78540 1/20 0.47
ALOX15 P16050 2/20 0.46
KMT2A Q03164 2/20 0.46
BLM P54132 1/20 0.46
PMP22 Q01453 1/20 0.46
PTGS1 P23219 1/20 0.46
SLC7A11 Q9UPY5 1/20 0.46
GRIK1 P39086 2/20 0.44
GRIK2 Q13002 2/20 0.44
GRM1 Q13255 2/20 0.44
GRM2 Q14416 2/20 0.44
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 2/20 0.42
GSR P00390 2/20 0.42
SLC7A5 Q01650 1/20 0.42
GRM8 O00222 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cystine SCHEMBL5223305 1.00 NOS2 (0.50) NOS2NOS1NOS3ARG1ARG2
Cystine SCHEMBL8332356 0.95 PTGS1 (0.50) NOS2NOS1NOS3ARG1ARG2
Cystine SCHEMBL8332360 0.95 PTGS1 (0.50) NOS2NOS1NOS3ARG1ARG2
Cystine SCHEMBL222059 0.95 PTGS1 (0.50) NOS2NOS1NOS3ARG1ARG2
Cystine SCHEMBL8332353 0.95 PTGS1 (0.50) NOS2NOS1NOS3ARG1ARG2
Cystine SCHEMBL21114356 0.95 PTGS1 (0.50) NOS2NOS1NOS3ARG1ARG2
Cystine SCHEMBL5018669 0.95 PTGS1 (0.50) NOS2NOS1NOS3ARG1ARG2
Cystine SCHEMBL10225 0.95 PTGS1 (0.50) NOS2NOS1NOS3ARG1ARG2
Cystine SCHEMBL10224 0.95 PTGS1 (0.50) NOS2NOS1NOS3ARG1ARG2
Cystine SCHEMBL127805 0.95 PTGS1 (0.50) NOS2NOS1NOS3ARG1ARG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1575900-A4 N-METHYL AMINO ACIDS UBIQUITOUS TECHNOLOGIES PTY LT (AU) 2007-02-21 EP disclosed
US-20050245432-A1 N-methyl amino acids UBIQUITOUS TECHNOLOGIES PTY. LTD. (AU) 2005-11-03 US disclosed
EP-1575900-A1 N-METHYL AMINO ACIDS UBIQUITOUS TECHNOLOGIES PTY LTD (AU) 2005-09-21 EP disclosed
WO-2004007427-A1 N-METHYL AMINO ACIDS UBIQUITOUS TECHNOLOGIES PTY LTD (AU) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245432-A1 N-methyl amino acids VIP, NPPA, PTMS NOS2 67/4885NOS1 95/4885NOS3 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.